The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

In July, the FDA issued a complete response letter (CRL) for Replimune's biologics license application for RP1 (vusolimogene ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

In this segment, Dr Luskin examines how patient-related factors influence treatment decisions in blastic plasmacytoid ...

Leyla O. Shune, MD, describes the available treatment options for patients with chronic graft-versus-host disease who are ...

Dr Benjamin George champions innovative oncology care in rural Nebraska, emphasizing collaboration and multidisciplinary ...

Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized ...

Here are the top 5 stories from 2025 about the advancements in prostate, kidney, and bladder cancers.

Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...

Luveltamab tazevibulin, a novel ADC, showed encouraging responses in platinum-resistant ovarian cancer, with a 32% ORR and a ...

Dr Benjamin George transforms oncology care in rural Nebraska, addressing unique challenges and enhancing access to vital ...

Marija Balic, MD, discusses the design and mechanism of the Oncodetect tumor-informed circulating tumor DNA assay for ...